The experimental anti-fibrotic and anti-inflammatory drug, pirfenidone, not only stopped kidney deterioration, it actually improved kidney function in study participants. A randomized, double-blind of 77 diabetes patients showed dramatic results in the group receiving the lowest dose of pirfenidone.
Pirfenidone works differently than the diabetes drugs currently in use, which treat high blood pressure and lower blood sugar levels. Pirfenidone seems to work by shutting down the growth factors that cause fibrosis, or scarring in blood vessels.
The next step is to perform larger clinical trials. To read more about this exciting potential advance in treating kidney disease online at Science Daily, >CLICK HERE<.